Oncotarget

Research Papers:

Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay

Aimée N. Laporte, Jennifer X. Ji, Limin Ma, Torsten O. Nielsen _ and Bertha A. Brodin

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:34384-34394. https://doi.org/10.18632/oncotarget.8882

Metrics: HTML 2044 views  |   ?  


Abstract

Aimée N. Laporte1,2, Jennifer X. Ji2, Limin Ma3, Torsten O. Nielsen1,2, Bertha A. Brodin3

1Department of Pathology and Laboratory Medicine, Vancouver Coastal Health Research Institute and Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

2Centre for Translational and Applied Genomics, British Columbia Cancer Agency, Vancouver, BC, Canada

3Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

Correspondence to:

Torsten O. Nielsen, email: torsten@mail.ubc.ca

Keywords: synovial sarcoma, proximity ligation assay, drug screening, HDAC inhibitors, protein-protein association

Received: September 09, 2015     Accepted: April 02, 2016     Published: April 21, 2016

ABSTRACT

Conventional cytotoxic therapies for synovial sarcoma provide limited benefit. Drugs specifically targeting the product of its driver translocation are currently unavailable, in part because the SS18-SSX oncoprotein functions via aberrant interactions within multiprotein complexes. Proximity ligation assay is a recently-developed method that assesses protein-protein interactions in situ. Here we report use of the proximity ligation assay to confirm the oncogenic association of SS18-SSX with its co-factor TLE1 in multiple human synovial sarcoma cell lines and in surgically-excised human tumor tissue. SS18-SSX/TLE1 interactions are disrupted by class I HDAC inhibitors and novel small molecule inhibitors. This assay can be applied in a high-throughput format for drug discovery in fusion-oncoprotein associated cancers where key effector partners are known.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8882